An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
Conditions
- Multiple Myeloma (MM)
- Non-Hodgkin Lymphoma (NHL)
Interventions
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators